Trial Design Optimizer

Trial Design Optimizer — Engineering the Experiment That Answers the Right Question

Trial design is where clinical development budgets are won or lost. A well-designed Phase 2 with an adaptive enrichment strategy can deliver the same signal as a conventional Phase 3 at one-third the cost. A poorly designed pivotal trial burns $150-300M and 3-4 years before delivering an uninterpretable result. The physician-scientist's edge in venture is recognizing design flaws that financial analysts cannot see: an inadequate run-in period, a composite endpoint that dilutes signal, a control arm that will be obsolete by readout.

Trial-cost benchmarks: for per-phase / per-patient trial cost and SCA/platform savings, use cost-estimator's references/development-cost-benchmarks.md rather than a separate table here.

ICH E9 R1 Estimand Framework

Every modern trial design begins with the estimand — the precise question the trial is designed to answer. ICH E9 R1 (2019) formalized this into five attributes that must be specified before choosing a statistical method:

The intercurrent events strategy is where most trial designs fail in venture diligence. Five strategies exist:

1. Treatment policy — analyze all patients regardless of what happens (ITT). Use when: the real-world question is "what happens if I prescribe this drug?"
2. Composite — incorporate the intercurrent event into the endpoint. Use when: discontinuation due to AEs is itself informative.
3. Hypothetical — estimate what would have happened without the intercurrent event. Use when: treatment switching confounds OS.
4. Principal stratum — analyze only patients who would not experience the intercurrent event. Use when: adherent subpopulations are of interest.
5. While on treatment — only measure while patients remain on treatment. Use when: pharmacodynamic endpoints matter.

Adaptive Design Taxonomy

Platform Trial Architecture

Platform trials (I-SPY 2, RECOVERY, GBM AGILE) represent the most capital-efficient trial design innovation in a decade:

• Shared control arm: 50-70% reduction in control patients needed across arms
• Bayesian adaptive randomization: shift enrollment to arms showing signal
• Seamless Phase 2/3: graduate arms directly to registration
• Cost efficiency: $15-25M per arm vs $50-100M for standalone trials
• Speed: 6-12 months to initial signal vs 18-24 months conventional

Basket, Umbrella, and Master Protocols

Synthetic Control Arm (SCA) Decision Engine

Synthetic control arms using real-world data (RWD) represent the highest-impact innovation in trial design economics. When appropriate, they can save $100-200M in development costs and accelerate enrollment by 30%.

SCA Appropriateness Decision Tree

START: Is there a well-established standard of care?
  |
  YES --> Is the natural history well-characterized with existing data?
  |         |
  |         YES --> Are primary endpoints objective and measurable in RWD?
  |         |         |
  |         |         YES --> Is the patient population identifiable in RWD sources?
  |         |         |         |
  |         |         |         YES --> SCA FEASIBLE: Proceed to data quality assessment
  |         |         |         NO  --> SCA NOT RECOMMENDED: population matching impossible
  |         |         NO  --> SCA NOT RECOMMENDED: endpoint not capturable in RWD
  |         NO  --> SCA NOT RECOMMENDED: insufficient historical context
  |
  NO --> Is this a single-arm trial in severe/rare disease?
            |
            YES --> SCA STRONGLY RECOMMENDED (FDA/EMA precedent in rare disease)
            NO  --> SCA NOT RECOMMENDED: randomized control required

SCA Data Quality Requirements

Regulatory Precedent for SCAs

• Bavencio (avelumab): FDA accepted external control for urothelial carcinoma maintenance
• Zolgensma (onasemnogene): SMA natural history as external comparator
• Blincyto (blinatumomab): Historical control for ALL accelerated approval
• FDA Draft Guidance (2023): Framework for using RWD/RWE in regulatory decision-making
• EMA Qualification: DARWIN EU platform for population-level RWD studies

Cost-Benefit Analysis

Sample Size Estimation Logic

Key Inputs for Power Calculation

1. Primary endpoint type: continuous, binary, time-to-event
2. Expected effect size: informed by Phase 2 data, competitor data, or mechanism
3. Alpha level: typically 0.025 one-sided (0.05 two-sided)
4. Power: 80% (minimum), 90% (preferred for pivotal)
5. Dropout rate: 10-30% depending on disease and duration
6. Interim analysis penalty: alpha spending function (O'Brien-Fleming, Lan-DeMets)

Rules of Thumb for Venture Diligence

• If a company claims <200 patients for a pivotal trial in a non-orphan indication, interrogate the assumptions
• Adaptive enrichment can reduce required N by 30-50% but introduces operational complexity
• Time-to-event trials: the number of events, not patients, drives power
• Bayesian designs can achieve equivalent evidence with 20-30% fewer patients but require regulatory pre-agreement

Structured Output Format

When generating a trial design recommendation, output:

TRIAL DESIGN RECOMMENDATION
============================
Therapeutic Hypothesis: [one-sentence hypothesis]
Development Stage: [Phase 1b/2/2b/3]
Target Population: [population definition]

ESTIMAND:
  Population: [target population]
  Treatment: [regimen]
  Endpoint: [primary endpoint]
  Intercurrent Event Strategy: [strategy + rationale]
  Summary Measure: [statistical measure]

RECOMMENDED DESIGN:
  Type: [conventional/adaptive/platform/basket]
  Adaptive Features: [if applicable]
  Estimated N: [sample size with assumptions]
  Control Arm: [active comparator/placebo/synthetic/external]
  Key Interim Analyses: [timing and decision rules]

SYNTHETIC CONTROL ASSESSMENT:
  Feasibility: [feasible/not recommended]
  Rationale: [3-4 sentences]
  Potential Savings: [$X-YM]
  Regulatory Risk: [low/moderate/high]

DESIGN RISKS:
  1. [Risk + mitigation]
  2. [Risk + mitigation]
  3. [Risk + mitigation]

TIMELINE ESTIMATE: [months to primary endpoint readout]
BUDGET ESTIMATE: [range based on design parameters]

Cross-Domain Connections

• Biotech-venture/endpoint-selection: Endpoint choice drives trial design parameters — an OS endpoint requires fundamentally different design than a surrogate
• Biotech-venture/biomarker-enrichment: Enrichment strategies affect design complexity, adding adaptive elements and modifying sample size requirements
• Biotech-venture/cost-estimator: Trial design directly determines development costs — adaptive designs, platform trials, and SCAs each have distinct cost profiles
• Research/spelunker: Deep research on regulatory precedent for novel trial designs, synthetic control arm acceptance, and adaptive methodology